Trial Profile

IMO 2125 + ribavirin versus peginterferon alfa-2a + ribavirin in patients with hepatitis C stratified for IL28B genotype.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 13 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tilsotolimod (Primary) ; Peginterferon alfa-2a; Ribavirin
Indications Hepatitis C
Focus Adverse reactions; Therapeutic Use

Most Recent Events

25 Feb 2012 Actual end date 20 Jan 2012 added as reported by EudraCT.
25 Feb 2012 Status changed from suspended to discontinued as reported by EudraCT.
10 May 2011 Actual initiation date 8 Apr 2011 added, trial location Hungary added as reported by European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com